Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension

Clinical Science

Volumn 116, Issue 6, 2009, Pages 497-505

  Lee, Tsung Ming ^a   Chen, Chien Chang ^a   Shen, Hsiu Nien ^a   Chang, Nen Chung ^b  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Chronic obstructive pulmonary disease (COPD); Dyspnoea; Endothelin 1 (ET 1); Exercise capacity; Pulmonary hypertension; Statin

Indexed keywords

ENDOTHELIN 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DYSPNEA; ECHOCARDIOGRAPHY; EXERCISE TEST; FEMALE; FORCED EXPIRATORY VOLUME; HEART RATE; HUMAN; LUNG ARTERY PRESSURE; LUNG CAPACITY; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; TREATMENT DURATION; URINARY EXCRETION; BLOOD; DRUG EFFECT; EXERCISE TOLERANCE; HEMODYNAMICS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ENDOTHELIN-1; EXERCISE TOLERANCE; FEMALE; HEMODYNAMICS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION, PULMONARY; LIPIDS; MALE; MIDDLE AGED; PRAVASTATIN; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 65549089130     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20080241     Document Type: Article

References (39)

1. Incalzi, R. A., Fuso, L., De Rosa, M. et al. (1999) Electrocardiographic signs of chronic cor pulmonale: a negative prognostic finding in chronic obstructive pulmonary disease. Circulation 99, 1600-1605
2. Cooper, R., Ghali, J., Simmons, B. E. and Castaner, A. (1991) Elevated pulmonary artery pressure. An independent predictor of mortality. Chest 99, 112-120
3. Weitzenblum, E., Kessler, R., Oswald, M. and Fraisse, P. (1994) Medical treatment of pulmonary hypertension in chronic lung disease. Eur. Respir. J. 7, 148-152
4. Wright, J. L., Levy, R. D. and Churg, A. (2005) Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment. Thorax 60, 605-609
5. Giaid, A., Yanagisawa, M., Langleben, D. et al. (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 328, 1732-1739
6. Cacoub, P., Dorent, R., Nataf, P. et al. (1997) Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc. Res. 33, 196-200
7. Ridker, P. M., Rifai, N., Pfeffer, M. A. et al. (1998) Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 98, 839-844
8. Lee, T. M., Chou, T. F. and Tsai, C. H. (2003) Effect of pravastatin on cardiomyocyte hypertrophy and ventricular vulnerability in normolipidemic rats after myocardial infarction. J. Mol. Cell. Cardiol. 35, 1449-1459
9. Lee, J. H., Lee, D. S., Kim, E. K. et al. (2005) Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am. J. Respir. Crit. Care Med. 172, 987-993
10. Sin, D. D. and Man, S. F. (2003) Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 107, 1514-1519
11. Pauwels, R. A., Buist, A. S., Calverley, P. M., Jenkins, C. R. and Hurd, S. S. (2001) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD)Workshop summary. Am. J. Respir. Crit. Care Med. 163, 1256-1276
12. Wilson, R. C. and Jones, P. W. (1989) A comparison of the visual analogue scale and modified Borg scale for the measurement of dyspnea during exercise. Clin. Sci. 76, 277-282
13. Berger, M., Haimowitz, A., Van Tosh, A., Berdoff, R. L. and Goldberg, E. (1985) Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J. Am. Coll. Cardiol. 6, 359-365
14. Bredikis, A. J. and Liebson, P. R. (1998) The echocardiogram in COPD: estimating right heart pressures. J. Respir. Dis. 19, 191-198
15. Barst, R. J., McGoon, M., Torbicki, A. et al. (2004) Diagnosis and differential assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43 (Suppl.), 40S-47S
16. Tsai, C. H., Lee, T. M., Wang, C. H. et al. (1997) Effects of dobutamine on aortic valve indexes in asymptomatic patients with bileaflet mechanical prostheses in the aortic valve position. Am. J. Cardiol. 79, 1546-1549
17. Pan, N. H., Lee, T. M., Lin, M. S., Huang, C. L. and Chang, N. C. (2006) Association of gliclazide and left ventricular mass in type 2 diabetic patients. Diabetes Res. Clin. Pract. 74, 121-128
18. Lee, T. M., Su, S. F. and Tsai, C. H. (2002) Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension 40, 67-73
19. Allain, C. C., Poon, L. S., Chan, C. S., Richmond, W. and Fu, P. C. (1974) Enzymatic determination of total serum cholesterol. Clin. Chem. 20, 470-475
20. Peng, W., Michael, J. R., Hoidal, J. R., Karwande, S. V. and Farrukh, I. S. (1998) ET-1 modulates KCa-channel activity and arterial tension in normoxic and hypoxic human pulmonary vasculature. Am. J. Physiol. 275, L729-L739
21. Sato, K., Morio, Y., Morris, K. G., Rodman, D. M. and McMurtry, I. F. (2000) Mechanism of hypoxic pulmonary vasoconstriction involves ETA receptor-mediated inhibition of KATP channel. Am. J. Physiol. Lung Cell. Mol. Physiol. 278, L432-L442
22. Kohan, D. E. (1993) Endothelins in the normal and diseased kidney. Am. J. Kidney Dis. 29, 2-26
23. Battistini, B., D'Orleans-Juste, P. and Sirois, P. (1993) Endothelins: circulating plasma levels and presence in other biologic fluids. Lab. Invest. 68, 600-627
24. Sofia, M., Mormile, M., Faraone, S. et al. (1994) Increased 24-hour endothelin-1 urinary excretion in patients with chronic obstructive pulmonary disease. Respiration 61, 263-268
25. Berbinschi, A. and Ketelslegers, J. M. (1989) Endothelin in urine. Lancet ii, 46
26. Cody, R. J., Haas, G. J., Binkley, P. F., Capers, Q. and Kelley, R. (1992) Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 85, 504-509
27. 2α formation. J. Cardiovasc. Pharmacol. 40, 868-874
28. Santus, P., Sola, A., Carlucci, P. et al. (2005) Lipid peroxidation and 5-lipoxygenase activity in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 171, 838-843
29. Repine, J. E., Bast, A. and Lankhorst, I. (1997) Oxidative stress in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 156, 341-357
30. Robertson, T. P., Dipp, M., Ward, J. P., Aaronson, P. I. and Evans, A. M. (2000) Inhibition of sustained hypoxic vasoconstriction by Y-27632 in isolated intrapulmonary arteries and perfused lung of the rat. Br. J. Pharmacol. 131, 5-9
31. Jeffery, T. K. and Morrell, N. W. (2002) Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog. Cardiovasc. Dis. 45, 173-202
32. Scharf, S. M., Iqbal, M., Keller, C., Criner, G., Lee, S. and Fessler, H. E. (2002) Hemodynamic characterization of patients with severe emphysema. Am. J. Respir. Crit. Care Med. 166, 314-322
33. Rakotoniaina, Z., Guerard, P., Lirussi, F. et al. (2006) The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin. Naunyn Schmiedebergs Arch. Pharmacol. 374, 195-206
34. Gulati, M., Black, H. R., Shaw, L. J. et al. (2005) The prognostic value of a nomogram for exercise capacity in women. N. Engl. J. Med. 353, 468-475
35. Frost, A. E., Langleben, D., Oudiz, R. et al. (2005) The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. Vasc. Pharmacol. 43, 36-39
36. Gomberg-Maitland, M., Huo, D., Benza, R. L., McLaughlin, V. V., Tapson, V. F. and Barst, R. J. (2007) Creation of a model comparing 6-minute walk test to metabolic equivalent in evaluating treatment effects in pulmonary arterial hypertension. J. Heart Lung Transplant. 26, 732-738
37. Amirhamzeh, M. M., Chant, H. J., Rees, J. L., Hands, L. J., Powell, R. J. and Campbell, W. B. (1997) A comparative study of treadmill tests and heel raising exercise for peripheral arterial disease. Eur. J. Vasc. Endovasc. Surg. 13, 301-305
38. Singh, S. J., Morgan, M. D., Scott, S., Walters, D. and Hardman, A. E. (1992) Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax 47, 1019-1024
39. Zwierska, I., Nawaz, S., Walker, R. D., Wood, R. F., Pockley, A. G. and Saxton, J. M. (2004) Treadmill versus shuttle walk tests of walking ability in intermittent claudication. Med. Sci. Sports Exercise 36, 1835-1840